Related Experiment Video
Updated: Jun 5, 2026
07:18
Cell-based Assay to Study Antibody-mediated Tau Clearance by Microglia
Published on: November 9, 2018
Antibody-based therapy in Alzheimer's disease
Refik Pul1, Richard Dodel, Martin Stangel
1Hannover Medical School, Department of Neurology, Carl-Neuberg-Str. 1, 30625 Hannover, Germany.
Expert Opinion on Biological Therapy
|January 26, 2011
Summary
Alzheimer's disease (AD) immunotherapy utilizes antibodies targeting amyloid-beta (Aβ) to combat neurodegeneration. Ongoing clinical trials explore novel antibody approaches for this incurable condition.
Area of Science:
- Neuroscience
- Immunology
- Pharmacology
Background:
- Alzheimer's disease (AD) is a leading cause of dementia, characterized by amyloid-beta (Aβ) plaques and tau tangles.
- Antibody-based immunotherapies are emerging as a promising therapeutic strategy for AD.
Purpose of the Study:
- To review the rationale and mechanisms of antibody immunotherapy in AD.
- To present current clinical trials and recent outcomes of therapeutic antibodies for AD.
Main Methods:
- Review of preclinical data and ongoing clinical trials for AD immunotherapies.
- Analysis of antibody-based approaches targeting amyloid-beta.
Main Results:
- Multiple antibody-based therapeutics are in clinical trials, including Phase III.
- Preclinical success in animal models supports antibody-based strategies.
Conclusions:
- Antibodies targeting Aβ offer a new avenue for AD treatment and understanding its pathology.
- Further research into Aβ and novel antibody approaches is crucial for AD drug development.
More Related Videos
Related Concept Videos
01:22Alzheimer's Disease: Treatment
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
01:26Alzheimer's Disease: Overview
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
01:23Alzheimer Disease ll: Pathophysiology
Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...
01:29Alzheimer Disease l: Introduction
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...